Tag

Your search for EASL 2015 returned 9 results.


Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, ...

Read More


EASL 2015 HCV Vaccine Lecture: Dr T. Baumert

  Please click here to view this important EASL 2015 HCV presentation by Thomas F. Baumert, MD. Thomas F. Baumert, MD is Professor of Medicine, head of Inserm Research Unit U1110, Institute of Viral and Liver Diseases, head of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Physician at the Center for Digestive Disease and Hepatol...

Read More


EASL Congress HCV Interview: Dr E. Lebovics

Regarding studies that are ongoing, what are you most excited about seeing at EASL? The results of which studies and what types of studies? Dr. Lebovics: Well, now that we are able to eliminate hepatitis C with all oral regimens in about 95% of standard patients, one area of great interest is extending our currently available regimens to special populations, ...

Read More


EASL Abstract Highlights – Dr T. Baumert

EASL Abstract O027 The Expression of Tumor Suppressor PTPRD is Down-Regulated in the Liver of Patients With HCV Infection and in Tumor Lesions of Patients With Hepatocellular Carcinoma Van Renne, F.H.T. Duong, C. Gondeau, D. Calabrese, N. Fontaine, A. Ababsa, S.C. Durand, P. Pessaux, M.H. Heim, T.F. Baumert, J. Lupberger. The International Liver Congress™ ...

Read More


EASL Pre-Congress HCV Interview: Dr R. Brown

Is there any data that is going to be presented at EASL that you’re really excited about? Are there any research studies that are going on right now that you’re really excited about? Dr. Brown: Right now we have two excellent FDA approved options for our genotype 1 Hepatitis C patient, but we have issues with patients who are not genotype 1, or those who have ...

Read More


EASL Pre-Congress HCV Interview: Dr P. Gaglio

What are your thoughts on birth cohort screening for hepatitis C? Should it be mandated by law? Dr. Gaglio: Sure, well I think that birth-cohort screening is an absolutely forward progress in terms of the screening of Hepatitis C, largely due to the fact that risk-based screening has been very ineffective. So, [birth-cohort screening] has been mandated by law and ...

Read More


EASL 2015 Hepatitis Abstract Choices: Dr. Ploss

For more information on the selected EASL 2015 Hepatitis abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G09 Targeting a Host-Cell Entry Factor Barricades Antiviral Resistant HCV Variants From On-Therapy Breakthrough In Human-Liver Mice Vercauteren K et al. ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Gaglio

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G15 The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Lebovics

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Current agents in special populations Abstract G02 Ledipasvir/Sofosbuvir with Ribavirin is Safe And Efficacious in Decompensated and Post Liver Transplantation Patients ...

Read More